Carlos L. Arteaga, M.D., a devoted cancer researcher and clinician, was named Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in September 2017. He also serves as Associate Dean of Oncology Programs. Dr. Arteaga is internationally recognized for his work in laboratory-based translational research and advancing the care of breast cancer patients. The majority of Dr. Arteaga’s career has been as a physician-scientist in Medical Oncology at the Vanderbilt-Ingram Cancer Center of Vanderbilt University, where he served as Associate Director for Translational/Clinical Research and Director of the Center for Cancer Targeted Therapies. At Vanderbilt, he also led a successful translational research program that includes a National Cancer Institute/National Institutes of Health SPORE award in breast cancer. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He has earned numerous accolades from the American Cancer Society, the American Association for Cancer Research (AACR), Susan G. Komen for the Cure Foundation, and the American Society of Clinical Oncology. A former President of the AACR, he serves on the boards of advisors of several cancer centers and breast cancer programs. Dr. Arteaga earned his medical degree from Facultad de Ciencias Médicas at the Universidad de Guayaquil in Ecuador. He trained in Internal Medicine at Emory University and in Medical Oncology at the University of Texas Health Science Center at San Antonio.
- Medical School
- Universidad de Guayaquil, Ecuador (1980)
- Emory University School of Medicine (1984), Internal Medicine
- University of Texas Health Science Center, San Antonio (1988), Hematology Oncology
- Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
- Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL Cancer Res. 2015 Jan 75 2 405-14
- PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
- Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL Hematol Oncol Stem Cell Ther 2014 Dec 7 4 142-8
- LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
- Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL J. Clin. Invest. 2014 Dec 124 12 5490-502
- Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
- Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM Oncotarget 2014 Oct 5 19 9049-64
- AACR Cancer Progress Report 2014.
- Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ Clin. Cancer Res. 2014 Oct 20 19 Suppl S1-S112
- PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?
- Mayer IA, Arteaga CL J. Clin. Oncol. 2014 Sep 32 27 2932-4
- Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.
- Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC Cancer Res. 2014 Sep 74 18 5184-94
- PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
- Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA Breast Cancer Res. 2014 Aug 16 4 406
- In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.
- McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC Biomed Opt Express 2014 Jul 5 7 2247-61
- Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
- Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL Breast Cancer Res. Treat. 2014 Jun 145 2 389-99